Showing 20 of 67 recruiting trials for “Neuroblastoma”
Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma
A Study on the Efficacy of GD2-CAR T Cells in the Treatment of Neuroblastoma
👨⚕️ Hai Yi, Ph.D, The General Hospital of Western Theater Command📍 1 site📅 Started Dec 2024View details ↗
DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations
A Multi-Arm, Platform Trial For Relapsed Neuroblastoma
Safety and Efficacy of Systemic Allogenic NK Cells in R/R Neuroblastoma
👨⚕️ Dr. Marzieh Ebrahimi, PhD. in Medical Immunology, Royan Institute📍 1 site📅 Started Nov 2024View details ↗
Phase I Study of Umbilical Cord Blood Natural Killer (NK) Cell Therapy for Children With High-risk, R/R Neuroblastoma.
RecruitingNCT06480526 ↗
Feasibility of Screening for Early Late Effects of Contemporary Therapy in High-Risk Neuroblastoma Survivors
👨⚕️ Sara Federico, MD, St. Jude Children's Research Hospital📍 1 site📅 Started Oct 2024View details ↗
Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined with the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).
N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma
👨⚕️ Brian Kushner, MD, Memorial Sloan Kettering Cancer Center📍 1 site📅 Started Jul 2024View details ↗
Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors
Hetrombopag in Promoting Platelet Engraftment After Auto-HSCT in Children With Neuroblastoma
RecruitingNCT06574698 ↗
Adding Of Naxitamb In Induction Therapy For High Risk Neuroblastoma
Multi-modular Chimeric Antigen Receptor Targeting GD2 in Neuroblastoma
RecruitingNCT06502210 ↗
Identification of New Gene Spliceosomes in Neuroblastoma
👨⚕️ Wenliang Ge, archiater, Nantong University Affiliated Hospital📍 1 site📅 Started Apr 2024View details ↗
Efficacy and Safety of Induction Chemotherapy for Olfactory Neuroblastoma (ESICON)
👨⚕️ Hongmeng Yu, Prof., Eye & ENT Hospital, Fudan University📍 1 site📅 Started Mar 2024View details ↗
Allogeneic Expanded Gamma Delta T Cells With GD2 Chemoimmunotherapy in Relapsed /Refractory Neuroblastoma or Refractory/ Relapsed Osteosarcoma
A Study of a Vaccine in Combination With Beta-glucan in People With Neuroblastoma
👨⚕️ Brian Kushner, MD, Memorial Sloan Kettering Cancer Center📍 7 sites📅 Started Sep 2023View details ↗
SPEARHEAD-3 Pediatric Study
👨⚕️ Fiorella Iglesias Cardenas, MD, Memorial Sloan Kettering Kids📍 10 sites📅 Started Sep 2023View details ↗
GPC2 CAR T Cells for Relapsed or Refractory Neuroblastoma and Metastatic Retinoblastoma
A Clinical Study Evaluating the Safety of Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-DOTA0-Tyr3-Octreotate in Children With Refractory or Recurrent Neuroblastoma Expressing Somatostatin Receptors.
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →